Pinnacle Bank Purchases New Position in Amgen, Inc. (NASDAQ:AMGN)

Pinnacle Bank purchased a new stake in Amgen, Inc. (NASDAQ:AMGN) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 322 shares of the medical research company’s stock, valued at approximately $63,000.

Other institutional investors have also bought and sold shares of the company. BlackRock Inc. boosted its holdings in Amgen by 2.0% in the 4th quarter. BlackRock Inc. now owns 46,127,396 shares of the medical research company’s stock valued at $8,979,621,000 after purchasing an additional 906,568 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its stake in shares of Amgen by 20,103.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 31,424,215 shares of the medical research company’s stock worth $161,000 after acquiring an additional 31,268,677 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Amgen by 4.7% during the 4th quarter. Northern Trust Corp now owns 9,182,050 shares of the medical research company’s stock worth $1,787,470,000 after acquiring an additional 408,675 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Amgen by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock worth $1,720,250,000 after acquiring an additional 482,760 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Amgen during the 4th quarter worth approximately $1,283,248,000. Institutional investors own 80.65% of the company’s stock.

Several brokerages have recently commented on AMGN. Mizuho set a $208.00 price target on Amgen and gave the stock a “buy” rating in a research note on Friday, April 12th. Royal Bank of Canada reissued a “neutral” rating and set a $192.00 price target on shares of Amgen in a research note on Tuesday. Citigroup raised Amgen from a “neutral” rating to a “buy” rating in a research note on Wednesday. Credit Suisse Group initiated coverage on Amgen in a research report on Monday. They set an “outperform” rating and a $208.00 price objective for the company. Finally, BidaskClub downgraded Amgen from a “hold” rating to a “sell” rating in a research report on Tuesday, April 23rd. One analyst has rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $209.30.

AMGN traded up $1.61 during trading on Wednesday, hitting $171.30. The company’s stock had a trading volume of 2,246,466 shares, compared to its average volume of 3,023,176. The company has a debt-to-equity ratio of 2.71, a quick ratio of 2.53 and a current ratio of 2.77. The company has a market capitalization of $103.09 billion, a PE ratio of 11.90, a price-to-earnings-growth ratio of 2.24 and a beta of 1.15. Amgen, Inc. has a twelve month low of $166.30 and a twelve month high of $210.19.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, April 30th. The medical research company reported $3.56 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.45 by $0.11. The company had revenue of $5.56 billion during the quarter, compared to the consensus estimate of $5.55 billion. Amgen had a return on equity of 71.02% and a net margin of 34.00%. Amgen’s revenue was up .1% on a year-over-year basis. During the same period in the previous year, the firm posted $3.47 EPS. As a group, equities research analysts forecast that Amgen, Inc. will post 13.94 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a dividend of $1.45 per share. The ex-dividend date is Thursday, May 16th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.39%. Amgen’s payout ratio is 40.28%.

In other news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $193.18, for a total transaction of $386,360.00. Following the completion of the sale, the director now directly owns 15,092 shares in the company, valued at approximately $2,915,472.56. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last 90 days, insiders have sold 6,000 shares of company stock valued at $1,115,580. Insiders own 0.25% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Pinnacle Bank Purchases New Position in Amgen, Inc. (NASDAQ:AMGN)” was originally posted by Sundance Herald and is owned by of Sundance Herald. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://sundanceherald.com/2019/05/22/pinnacle-bank-invests-63000-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Article: Do investors pay a separate front-end load every time they buy additional shares?

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply